Abstract 7MO
Background
Oritinib (SH-1028) is a third-generation EGFR-TKI selectively targeting both sensitive EGFR and EGFR T790M mutations. Herein, we report the efficacy and safety of oritinib in EGFR T790M-positive advanced NSCLC patients from the phase II study (NCT03823807).
Methods
Eligible patients were locally advanced or metastatic NSCLC patients aged ≥ 18 years, with centrally confirmed EGFR T790M mutation. Patients with asymptomatic, stable CNS metastases were eligible into the study. Oritinib 200 mg was given orally once daily until disease progression or unacceptable toxicity. Primary efficacy endpoint was objective response rate (ORR). Secondary efficacy endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
Between December 2019 and March 2021, 228 patients were enrolled and 227 patients received at least one dose of oritinib. The median age of 227 patients was 62 years old, 57.3% of patients were female and 24.7% received systemic chemotherapies. At data cutoff (September 17, 2021), 137 of 227 patients achieved confirmed partial responses with ORR of 60.4% (95% CI: 42.4%, 68.8%) by IRaC. The DCR was 92.5% (88.3%, 95.6%), the mPFS was 12.6 months (95% CI: 9.7, 15.3), the mDOR was 12.5 months (95% CI: 11.2, NA) and the mOS was immature. The most common (≥10%) treatment-emergent adverse events (TEAEs) included diarrhea (45.4%), increased blood creatine phosphokinase (26.0%), anaemia (20.3%), decreased white blood cell count (15.4%), decreased appetite (15.0%), increased blood creatine phosphokinase isoenzyme (13.2%), nausea (13.2%), vomiting (13.2%), increased serum creatine (12.8%), upper respiratory tract infection (12.3%), increased aspartate aminotransferase (11.9%), cough(11.9%), decreased platelet count (11.0%), constipation (10.6%). Grade≥3 TEAEs included increased blood creatine phosphokinase (4.0%), hypertension (3.1%), death (2.6%), diarrhea (2.2%). No interstitial lung disease were reported.
Conclusions
Oritinib demonstrated potential clinical benefit and tolerable in advanced NSCLC patients with EGFR T790M mutation.
Clinical trial identification
NCT03823807; January 30, 2019.
Legal entity responsible for the study
NanJing Sanhome Pharmaceutical Co., Ltd.
Funding
NanJing Sanhome Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: Updated overall survival results from the phase 3 CameL-sq trial
Presenter: Caicun Zhou
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
4MO - Final Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMnsqNSCLC) in the Phase 3 ORIENT -11 Study
Presenter: Yunpeng Yang
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
5MO - Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Presenter: Edward Garon
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score <b>≥</b>50%: KEYNOTE-598 3-year follow-up
Presenter: Delvys Rodriguez Abreu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
2MO - Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
Presenter: Shun Lu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
8MO - The efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer
Presenter: Shun Lu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant of 3MO, 4MO, 5MO and 6MO
Presenter: Luis Paz-Ares
Session: Mini Oral session 2
Resources:
Slides
Webcast
Invited Discussant of 2MO, 7MO and 8MO
Presenter: Natasha Leighl
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast